ENMD-2076

SynDRA canonical compound SYN0018870 — structure-anchored drug synonym record

Clinical phase	Phase 2
Primary target(s)	AURKA \| CSF1R \| EPHA1 \| FGFR1 \| FGFR2 \| FGFR3 \| FLT3 \| FLT4 \| KDR \| KIT \| PDGFRA \| PTK2 \| SRC
Mechanism of action	Aurora kinase inhibitor \| FLT3 inhibitor \| VEGFR inhibitor

All known targets

L-(+) TARTRATE SALT OF ENMD-981693
ENMD 2076
(E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine
UNII-J6U9WP10T7
ENMD2076
J6U9WP10T7
CHEMBL482968
6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine
6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE
ENMD-981693
MLS006011042
SCHEMBL596481
GTPL7885
SCHEMBL15668060
SCHEMBL10122872
ENND-2076
EX-A235
DTXSID60239430
MolPort-009-679-391
AOB87159
RefChem:136939
DTXCID80161921
KXQ762CQTH
L-(+) Tartrate salt of ENMD-981693
MFCD18074523
SCHEMBL597664
orb1305600
SCHEMBL29355178
BDBM734441
ENMD-2076?
GLXC-90268
C21H25N7
BDBM50277584
HY-10987A
MFCD16619371
NSC800094
s1181
AKOS030527014
CCG-264851